San Carlos, CA, United States of America

Jeffrey L Cleland

This inventor holds 47 USPTO granted patents and 21 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Polypeptide Therapeutics. Top assignees: Genentech, Inc., Graybug Vision, Inc., Amunix Operating Inc.. Active years: 1996-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey L Cleland. Retrieved from https://idiyas.com/inventor/jeffrey-l-cleland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47 (Patent Applications = 21)

% Patents Active = 76.6

CIPO Patents = 4 (Patent Applications = 11)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 4.0

ph-index = 18

Forward Citations = 1,748(Granted Patents)

Company Filing History:

Amunix Operating Inc.

patents

4. 2 out of 11

Amunix Pharmaceuticals, Inc

Graybug Visioon, Inc.

Years Active: 1996-2024

Loading Chart...

Areas of Expertise:

Extended Recombinant Polypeptides

Microparticles

Ocular Disorders

Sustained Release

Bioerodible Polymers

Controlled Release

Protein Formulation

Growth Hormone Polypeptides

Microencapsulation

Injection Vehicles

Therapeutic Compositions

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071456 - Extended recombinant polypeptides and compositions comprising same (2024-08-27),

2. 11564890 - Aggregating microparticles for medical therapy (2023-01-31),

3. 11548861 - Drugs and compositions for the treatment of ocular disorders (2023-01-10),

4. 11331276 - Aggregating microparticles for medical therapy (2022-05-17),

5. 11160870 - Extended release microparticles and suspensions thereof for medical therapy (2021-11-02),

6. 10961287 - Extended recombinant polypeptides and compositions comprising same (2021-03-30),

7. 10485876 - Compounds and compositions for the treatment of ocular disorders (2019-11-26),

8. 10441548 - Aggregating microparticles for medical therapy (2019-10-15),

9. 10159747 - Compounds and compositions for the treatment of ocular disorders (2018-12-25),

10. 10117950 - Compounds and compositions for the treatment of ocular disorders (2018-11-06),

11. 10111964 - Compounds and compositions for the treatment of ocular disorders (2018-10-30),

12. 10098965 - Compounds and compositions for the treatment of ocular disorders (2018-10-16),

13. 10000543 - Glucose-regulating polypeptides and methods of making and using same (2018-06-19),

14. 9956302 - Compounds and compositions for the treatment of ocular disorders (2018-05-01),

15. 9926351 - Extended recombinant polypeptides and compositions comprising same (2018-03-27),

Title: The Innovative Journey of Jeffrey L Cleland

Introduction: Jeffrey L Cleland, a pioneering inventor based in San Carlos, CA (US), has made significant contributions to the field of innovations and patents with his groundbreaking ideas and inventions.

Latest Patents: Jeffrey L Cleland holds several patents in various industries, including biotechnology, healthcare, and electronics. His recent patents focus on cutting-edge medical devices and sustainable energy solutions.

Career Highlights: With a career spanning over two decades, Jeffrey L Cleland has established himself as a leading figure in the world of inventions. He has worked with renowned research institutions and companies to bring his ideas to life, revolutionizing the way we approach technology and healthcare.

Collaborations: Throughout his career, Jeffrey L Cleland has collaborated with top universities, research institutions, and innovative companies to develop and commercialize his inventions. His partnerships have led to the creation of groundbreaking products that have had a lasting impact on society.

Conclusion: Jeffrey L Cleland's passion for innovation and his relentless pursuit of excellence have solidified his position as a visionary inventor. His dedication to pushing the boundaries of what is possible continues to inspire the next generation of inventors and innovators worldwide.

Profile summary based on public USPTO records.